Article By:
Zacks Investment Research
Sunday, January 7, 2024 9:00 AM EDT
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech stocks that will likely perform well in 2024.
Regeneron Pharmaceuticals’ Dupixent Has Multi-Billion-Dollar Potential: Polen Capital
Note it has only been approved in Japan. And only for those whom existing treatments are ineffective. So that's a MUCH smaller market. How small I don't know. But not enough to make me bite. $REGN